Author: admin

“Menopause Drugs Market”

(Albany, USA) DelveInsight’s “Menopause Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Menopause, historical and forecasted epidemiology as well as the Menopause market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Menopause, offering comprehensive insights into the Menopause revenue trends, prevalence, and treatment landscape. The report delves into key Menopause statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Menopause therapies. Additionally, we cover the landscape of Menopause clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Menopause treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Menopause space.

To Know in detail about the Menopause market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menopause Market Forecast

Some of the key facts of the Menopause Market Report: 

• The Menopause market size was valued ~USD 10,968 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2022, hormonal therapy accounted for approximately 63% of the total market share in the 7MM. However, its market share is expected to decline by 2034 as non-hormonal therapies become more prevalent.

• Key Menopause Companies: GlaxoSmithKline, Pfizer, Centro A.F. de Estudios Tecnologicos, S.A., IBSA Institut Biochimique SA, Massachusetts General Hospital, Watson Pharmaceuticals, Ausio Pharmaceuticals, LLC, Bayer, TherapeuticsMD, Organon and Co, Duramed Research, Noema Pharma AG, Unimed Pharmaceuticals, and others

• Key Menopause Therapies: GSK232802, DVS-233, Estradiol and Progesterone, Progesterone, Paroxetine, Premarin® (oral) vs. Alora® (transdermal), S-equol, LNG IUS, Estradiol, tibolone, DR-2041a, NOE-115, MELSMON, and others.

• In May 2023, The US FDA recently approved VEOZAH (fezolinetant), a non-hormonal treatment that has demonstrated a significant reduction in the frequency and severity of moderate-to-severe VMS. VEOZAH has received approval in the United States, is under review in Europe, and is being introduced to the emerging market in Japan.

• In 2022, the total number of menopause cases in the 7MM was 100,133,055. This number is expected to decline during the forecast period (2023-2034), primarily due to a decreasing female geriatric population in most of the countries within the 7MM.

• In the 7MM, the stages of menopause among women were generally classified into perimenopausal (ages 40–65), postmenopausal (ages 40–65), and premature menopause (under 40 years).

• In 2022, hot flashes were the most commonly observed symptom among women in menopause across the 7MM, making it the predominant condition during this stage of life.

• In 2022, the total number of women in menopause across the EU4 (France, Germany, Italy, and Spain) and the UK was recorded at 41,300,409 cases, with projections indicating a decline in the coming years.

• According to DelveInsight’s estimates, there were around 29,751,360 cases of hot flashes and 28,121,149 cases of night sweats in 2022, with these numbers expected to increase by 2034 during the study period.

• The current selection of drugs for menopause includes a wide variety of medications. Notable emerging therapies in this area include DONESTA, BAY3427080, and VEOZAH, among others. Ongoing research and clinical trials have the potential to significantly impact the menopause treatment market.

Menopause Overview

Menopause is a natural biological process marking the end of a woman’s reproductive years. It occurs when the ovaries stop producing eggs, leading to a decline in estrogen and progesterone hormone levels. This transition typically happens between the ages of 45 and 55 but can occur earlier or later.

Menopause is confirmed after 12 consecutive months without a menstrual period. Common symptoms include hot flashes, night sweats, mood changes, sleep disturbances, and dryness.

Get a Free sample for the Menopause Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/menopause-market-forecast

Menopause Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Menopause Epidemiology Segmentation:

The Menopause market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Number of Women in Menopause in the 7MM

• Stage-specific Distribution of Women in Menopause in the 7MM

• Age-specific Distribution of Women in Menopause in the 7MM

• Number of Women in Menopause with Moderate-to-severe Vasomotor Symptoms in the 7MM

• Number of Women in Menopause with Vasomotor Symptoms in the 7MM

Download the report to understand which factors are driving Menopause epidemiology trends @ Menopause Epidemiology Forecast

Menopause Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menopause market or expected to get launched during the study period. The analysis covers Menopause market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menopause Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Menopause Therapies and Key Companies

• GSK232802: GlaxoSmithKline

• DVS-233: Pfizer

• Estradiol and Progesterone: Centro A.F. de Estudios Tecnologicos, S.A.

• Progesterone: IBSA Institut Biochimique SA

• Paroxetine: Massachusetts General Hospital

• Premarin® (oral) vs. Alora® (transdermal): Watson Pharmaceuticals

• S-equol: Ausio Pharmaceuticals, LLC

• LNG IUS: Bayer

• Estradiol: TherapeuticsMD

• tibolone: Organon and Co

• DR-2041a: Duramed Research

• NOE-115: Noema Pharma AG

• tibolone: Organon and Co

• MELSMON: Unimed Pharmaceuticals

Discover more about therapies set to grab major Menopause market share @ Menopause Treatment Landscape

Menopause Market Strengths

• The increasing geriatric population, rising awareness, and improved dietary habits will strengthen the menopause market

Menopause Market Opportunities

• Development of efficacious once-monthly non-hormonal alternatives to HRTs for symptom management

Scope of the Menopause Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Menopause Companies: GlaxoSmithKline, Pfizer, Centro A.F. de Estudios Tecnologicos, S.A., IBSA Institut Biochimique SA, Massachusetts General Hospital, Watson Pharmaceuticals, Ausio Pharmaceuticals, LLC, Bayer, TherapeuticsMD, Organon and Co, Duramed Research, Noema Pharma AG, Unimed Pharmaceuticals, and others

• Key Menopause Therapies: GlaxoSmithKline, Pfizer, Centro A.F. de Estudios Tecnologicos, S.A., IBSA Institut Biochimique SA, Massachusetts General Hospital, Watson Pharmaceuticals, Ausio Pharmaceuticals, LLC, Bayer, TherapeuticsMD, Organon and Co, Duramed Research, Noema Pharma AG, Unimed Pharmaceuticals, and others

• Menopause Therapeutic Assessment: Menopause current marketed and Menopause emerging therapies

• Menopause Market Dynamics: Menopause market drivers and Menopause market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Menopause Unmet Needs, KOL’s views, Analyst’s views, Menopause Market Access and Reimbursement 

To know more about Menopause companies working in the treatment market, visit @ Menopause Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Menopause Market Report Introduction

2. Executive Summary for Menopause

3. SWOT analysis of Menopause

4. Menopause Patient Share (%) Overview at a Glance

5. Menopause Market Overview at a Glance

6. Menopause Disease Background and Overview

7. Menopause Epidemiology and Patient Population

8. Country-Specific Patient Population of Menopause 

9. Menopause Current Treatment and Medical Practices

10. Menopause Unmet Needs

11. Menopause Emerging Therapies

12. Menopause Market Outlook

13. Country-Wise Menopause Market Analysis (2020–2034)

14. Menopause Market Access and Reimbursement of Therapies

15. Menopause Market Drivers

16. Menopause Market Barriers

17.  Menopause Appendix

18. Menopause Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menopause Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight | Bayer, GSK, Pfizer, Centro A.F. de Estudios Tecnologicos, S.A.,

“Sepsis Clinical Trials”

(Albany, United States) As per DelveInsight’s assessment, globally, Sepsis pipeline constitutes 25+ key companies continuously working towards developing 30+ Sepsis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Sepsis Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sepsis Market.

The Sepsis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Sepsis Pipeline Analysis

Some of the key takeaways from the Sepsis Pipeline Report:

• Sepsis Companies across the globe are diligently working toward developing novel Sepsis treatment therapies with a considerable amount of success over the years. 
• Sepsis companies working in the treatment market are AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics and others, are developing therapies for the Sepsis treatment 
• Emerging Sepsis therapies such as Enibarcimab, M 6229, SNIPR 001, and others are expected to have a significant impact on the Sepsis market in the coming years.
• In April 2024, Enlivex announced the 28-topline data from the Phase II trial evaluating ALLOCETRA.
• In April 2024, AdrenoMed announced that the US FDA granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment of septic shock.

Sepsis Overview

Sepsis is a life-threatening medical condition that arises when the body’s response to an infection causes widespread inflammation. This inflammation can lead to tissue damage, organ failure, and death if not promptly treated. Sepsis is most commonly triggered by bacterial infections but can also result from viral, fungal, or parasitic infections. The condition progresses through three stages: sepsis, severe sepsis, and septic shock. Symptoms of sepsis include fever, increased heart rate, rapid breathing, and confusion. As it advances, symptoms may escalate to include significant drop in blood pressure, difficulty breathing, and potential organ dysfunction.

Prompt diagnosis and treatment are critical in managing sepsis. Treatment typically involves antibiotics to combat the infection, intravenous fluids to maintain blood pressure and hydration, and other supportive measures such as oxygen therapy or mechanical ventilation if needed. Early detection through awareness of symptoms and rapid intervention can significantly improve outcomes. Preventative measures include proper hygiene, timely vaccination, and infection control practices in healthcare settings. Despite advances in medical care, sepsis remains a leading cause of death globally, highlighting the need for ongoing research and improved clinical protocols to enhance early detection and treatment.

Get a Free Sample PDF Report to know more about Sepsis Pipeline Therapeutic Assessment- Sepsis Treatment Market

Sepsis Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sepsis Molecule Type

Sepsis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Sepsis Pipeline Therapeutics Assessment

• Sepsis Assessment by Product Type
• Sepsis By Stage and Product Type
• Sepsis Assessment by Route of Administration
• Sepsis By Stage and Route of Administration
• Sepsis Assessment by Molecule Type
• Sepsis by Stage and Molecule Type

DelveInsight’s Sepsis Report covers around 30+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sepsis product details are provided in the report. Download the Sepsis pipeline report to learn more about the emerging Sepsis therapies- https://www.delveinsight.com/report-store/sepsis-pipeline-insight

Sepsis Pipeline Analysis:

The Sepsis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Sepsis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.
• Sepsis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sepsis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sepsis market.

Download Sample PDF Report to know more about Sepsis drugs and therapies- Sepsis Clinical Trials and FDA Approvals

Scope of Sepsis Pipeline Drug Insight    

• Coverage: Global
• Key Sepsis Companies: AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics and others.
• Key Sepsis Therapies: Enibarcimab, M 6229, SNIPR 001, and others.
• Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
• Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers 

Request for Sample PDF Report for Sepsis Pipeline Assessment and clinical trials – Sepsis Drugs in Pipeline

Table of Contents

1. Sepsis Report Introduction

2. Sepsis Executive Summary

3. Sepsis Overview                                 

4. Sepsis- Analytical Perspective In-depth Commercial Assessment

5. Sepsis Pipeline Therapeutics

6. Sepsis Late Stage Products (Phase II/III)

7. Sepsis Mid Stage Products (Phase II)

8. Sepsis Early Stage Products (Phase I)

9. Sepsis Preclinical Stage Products

10. Sepsis Therapeutics Assessment

11. Sepsis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sepsis Companies

14. Sepsis Key Products

15. Sepsis Unmet Needs

16 . Sepsis Market Drivers and Barriers

17. Sepsis Future Perspectives and Conclusion

18. Sepsis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sepsis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration and Companies by DelveInsight

“Pompe Disease Clinical Trials”

(Albany, USA) DelveInsight’s, “Pompe Disease Pipeline Insights, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample report of Pompe Disease @ Pompe Disease Pipeline Report

Some of the key highlights from the Pompe Disease Pipeline report:

• The Pompe Disease Pipeline report offers a rich analysis of 15+ key players and 20+ key therapies.
• Pompe Disease pipeline comprises therapies in different stages of the clinical phase such as include Cipaglucosidase alfa, SPK-3006, ACTUS 101, AT845, RP A501, AOC-Pompe disease, AVR RD 03, GYS1 Program, ETV-GAA, and many others expected to enter the Pompe Disease market in the coming years.
• Key companies strengthening the Pompe Disease Pipeline are Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, Novartis AG, Fresenius Kabi AG, Akorn Incorporated, Teva Pharmaceutical, Mylan N.V, Johnsons & Johnsons, F. Hoffman-La Roche Ltd., Trinity Biotech plc, and others.
• On April 2024, Astellas Gene Therapies announced results of a Study to Evaluate Seroprevalence of Antibodies to AAV8 and Assessment of Biomarkers in Patients With Late-Onset Pompe Disease.
• On April 2024, Amicus Therapeutics announced results of an Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease.
• On March 2024, Genzyme, a Sanofi Company announced results of a Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatment.
• On November 2023, Spark Therapeutics, Inc announced results of a Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease.
• On June 2023, Asklepios Biopharmaceutical, Inc announced results of a Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe Disease.

Pompe Disease Overview

Pompe disease, also known as glycogen storage disease type II, is a rare genetic disorder characterized by the buildup of glycogen in cells, particularly within muscles. This accumulation impairs the function of various organs, predominantly affecting the muscles, heart, and liver. Pompe disease is caused by mutations in the GAA gene, leading to deficiency or dysfunction of the enzyme acid alpha-glucosidase (GAA), which is responsible for breaking down glycogen. Symptoms can vary widely in severity and may include muscle weakness, respiratory difficulties, enlarged heart (cardiomegaly), and liver problems. Early onset Pompe disease typically presents in infancy, while late-onset forms may manifest later in childhood or adulthood. Treatment options include enzyme replacement therapy (ERT) to supplement the deficient enzyme and manage symptoms, along with supportive care to address specific complications. Regular monitoring and management by healthcare professionals are essential for optimizing outcomes in individuals with Pompe disease.

Learn more about Pompe Disease treatment therapies. Contact to receive a sample @ Pompe Disease Treatment Market

Pompe Disease Pipeline Drugs

• Cipaglucosidase alfa – Amicus Therapeutics
• SPK-3006 – Spark Therapeutics
• AT845 – Audentes Therapeutics
• ACTUS 101 – Asklepios Biopharmaceutical
• RP A501 – Rocket Pharmaceuticals
• AVR-RD-03 – AVROBIO
• AOC-Pompe disease – Avidity Biosciences

Pompe Disease Therapeutic Assessment

The Pompe Disease Pipeline report lays down complete insights into active Pompe Disease pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono
• Combination

By Stage

• Discovery
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type

• Gene therapies

Recombinant fusion proteins

• Small interfering RNA
• Cell therapies
• Monoclonal antibodies

By Route of Administration

• Intravenous
• Parenteral

By Mechanism of Action

• Alpha-glucosidase replacements
• Glycogen synthase kinase modulators
• RNA interference
• Gene transference

By Targets

• Alpha-glucosidase
• Gene replacement
• Glycogen synthase kinase

Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies @ Pompe Disease Therapeutics Assessment

Scope of the Pompe Disease Pipeline Report

• Coverage: Global
• Key Pompe Disease Companies: Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, Novartis AG, Fresenius Kabi AG, Akorn Incorporated, Teva Pharmaceutical, Mylan N.V, Johnsons & Johnsons, F. Hoffman-La Roche Ltd., Trinity Biotech plc, and others.
• Key Pompe Disease Pipeline Therapies: Cipaglucosidase alfa, SPK-3006, ACTUS 101, AT845, RP A501, AIM vectors, AVR RD 03, GYS1 Program, ETV-GAA, Research programme: glycogen storage disease type II therapy, AOC-Pompe disease, and others.

Visit to know more of what’s covered @ Pompe Disease Clinical Trials and FDA Approvals

Table of Contents

1. Report Introduction
2. Pompe Disease Disease Overview
3. Pompe Disease Pipeline Outlook
4. Comparative Analysis
5. Pompe Disease Therapeutic Products in Clinical Stage
6. Pompe Disease Late Stage Products (Phase III)
7. Pompe Disease Mid Stage Products (Phase II)
8. Pompe Disease Early Stage Products (Phase I)
9. Pompe Disease Therapeutic Products in Non-clinical Stage
10. Pompe Disease Preclinical and Discovery Stage Products
11. Pompe Disease – DelveInsight’s Analytical Perspective
12. In-depth Commercial Assessment
13. Pompe Disease Collaboration Deals
14. Pompe Disease Therapeutics Pipeline Analysis
15. Inactive Pompe Disease Pipeline Products
16. Pompe Disease Companies
17. Pompe Disease Unmet Needs
18. Pompe Disease Market Drivers and Barriers
19. Pompe Disease- Future Perspectives and Conclusion
20. Appendix
21. Report Methodology
22. Pompe Disease Consulting Services
23. Disclaimer
24. About DelveInsight

Competitive Intelligence

DelveInsight’s Competitive Intelligence Services provide real-time and actionable research insights through operations that are reinforced by a fundamental goal of securing best-in-class pharmaceutical market intelligence and provide analysis and insights through our team that results in significant contributions towards the pharmaceutical market intelligence consulting goal of our partners.

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Clinical Trials 2024: EMA, PDMA, FDA Approval, Medication, Pipeline, Drugs, Treatment Market, ROA, MOA and Companies by DelveInsight

“Hidradenitis Suppurativa Clinical Trials”

(Albany, United States) As per DelveInsight’s assessment, globally, Hidradenitis Suppurativa pipeline constitutes 24+ key companies continuously working towards developing 24+ Hidradenitis Suppurativa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hidradenitis Suppurativa Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hidradenitis Suppurativa Market.

The Hidradenitis Suppurativa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Hidradenitis Suppurativa Pipeline Analysis

Some of the key takeaways from the Hidradenitis Suppurativa Pipeline Report:

• Hidradenitis Suppurativa Companies across the globe are diligently working toward developing novel Hidradenitis Suppurativa treatment therapies with a considerable amount of success over the years. 
• Hidradenitis Suppurativa companies working in the treatment market are InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others, are developing therapies for the Hidradenitis Suppurativa treatment 
• Emerging Hidradenitis Suppurativa therapies such as Vilobelimab, Secukinumab, Avacopan, Imsidolimab, Spesolimab, and others are expected to have a significant impact on the Hidradenitis Suppurativa market in the coming years.   
• In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.
• In April 2022, AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, and moderate-to-severe hidradenitis suppurativa; Imsidolimab top-line data from the HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in the third quarter of 2022.

Hidradenitis Suppurativa Overview

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts primarily affecting areas rich in apocrine glands such as the armpits, groin, buttocks, and more. The exact cause of Hidradenitis suppurativa is not well understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors. Hidradenitis suppurativa typically begins after puberty and can persist for many years, significantly impacting a patient’s quality of life due to pain, scarring, and recurrent flare-ups. Early stages present with tender lumps, which can rupture and release pus, leading to foul-smelling discharge. As the disease progresses, it can form interconnected tunnels under the skin. Diagnosis is primarily clinical, based on the characteristic lesions and their distribution. Treatment options are tailored to the severity of the disease and include lifestyle modifications, antibiotics, anti-inflammatory medications, hormonal therapy, and, in severe cases, surgical intervention to remove affected skin. Recent advances in biologic therapies targeting specific inflammatory pathways offer new hope for patients with moderate to severe Hidradenitis suppurativa. Managing Hidradenitis suppurativa often requires a multidisciplinary approach involving dermatologists, surgeons, and pain specialists to improve outcomes and patient well-being.

Get a Free Sample PDF Report to know more about Hidradenitis Suppurativa Pipeline Therapeutic Assessment- Hidradenitis suppurativa Treatment Market

Hidradenitis Suppurativa Route of Administration

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hidradenitis Suppurativa Molecule Type

Hidradenitis Suppurativa Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Hidradenitis Suppurativa Pipeline Therapeutics Assessment

• Hidradenitis Suppurativa Assessment by Product Type
• Hidradenitis Suppurativa By Stage and Product Type
• Hidradenitis Suppurativa Assessment by Route of Administration
• Hidradenitis Suppurativa By Stage and Route of Administration
• Hidradenitis Suppurativa Assessment by Molecule Type
• Hidradenitis Suppurativa by Stage and Molecule Type

DelveInsight’s Hidradenitis Suppurativa Report covers around 24+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hidradenitis Suppurativa product details are provided in the report. Download the Hidradenitis Suppurativa pipeline report to learn more about the emerging Hidradenitis Suppurativa therapies- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Hidradenitis Suppurativa Pipeline Analysis:

The Hidradenitis Suppurativa pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
• Hidradenitis Suppurativa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market.

Download Sample PDF Report to know more about Hidradenitis Suppurativa drugs and therapies- Hidradenitis suppurativa Clinical Trials and FDA Approvals

Scope of Hidradenitis Suppurativa Pipeline Drug Insight    

• Coverage: Global
• Key Hidradenitis Suppurativa companies: InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.
• Emerging Hidradenitis Suppurativa therapies: Vilobelimab, Secukinumab, Avacopan, Imsidolimab, Spesolimab, and others.  
• Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies
• Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers 

Request for Sample PDF Report for Hidradenitis Suppurativa Pipeline Assessment and clinical trials – Hidradenitis suppurativa Drugs and Therapies

Table of Contents

1. Hidradenitis Suppurativa Report Introduction

2. Hidradenitis Suppurativa Executive Summary

3. Hidradenitis Suppurativa Overview:

4. Hidradenitis Suppurativa- Analytical Perspective In-depth Commercial Assessment

5. Hidradenitis Suppurativa Pipeline Therapeutics

6. Hidradenitis Suppurativa Late Stage Products (Phase II/III)

7. Hidradenitis Suppurativa Mid Stage Products (Phase II)

8. Hidradenitis Suppurativa Early Stage Products (Phase I)

9. Hidradenitis Suppurativa Preclinical Stage Products

10. Hidradenitis Suppurativa Therapeutics Assessment

11. Hidradenitis Suppurativa Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hidradenitis Suppurativa Companies

14. Hidradenitis Suppurativa Key Products

15. Hidradenitis Suppurativa Unmet Needs

16 . Hidradenitis Suppurativa Market Drivers and Barriers

17. Hidradenitis Suppurativa Future Perspectives and Conclusion

18. Hidradenitis Suppurativa Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

“Oncolytic Virus Therapies Market”

(Albany, USA) DelveInsight’s Oncolytic Virus Therapies Market Insights report includes a comprehensive understanding of current treatment practices, Oncolytic Virus Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan]. 

To know more about the Oncolytic Virus Therapies Market report offerings, click here @ Oncolytic Virus Therapies Market Forecast

Some facts of the Oncolytic Virus Therapies market report are:

• In 2021, the total Oncolytic Virus Therapies market size was approximately USD 122 million which is expected to rise during the study period (2020–2034).
• In 2021, the total Oncolytic Virus Therapies target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2020–2034.
• Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47D; Daiichi Sankyo) approved in Japan in 2021.
• Some of the companies working in the Oncolytic Virus Therapies market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo and others.
• In November 2023, Genelux announced that the US FDA granted Fast Track designation (FTD) for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum-resistant/refractory ovarian cancer.

Request for Sample Request @ Oncolytic Virus Therapeutic Assessment and Clinical Trials

Oncolytic Virus Therapies Overview

Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. Oncolytic Virus Therapies is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.

Oncolytic Virus Therapies Epidemiology Segmentation

According to DelveInsight estimates, there were approximately 632K Oncolytic Virus Therapies targeted patient pool in the 7MM in 2021.

Among the 7MM countries, the US had the highest incidence of Oncolytic Virus Therapies in 2021.

The Oncolytic Virus Therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident cases of selected cancer types
• Target Patient Pool of Oncolytic Virus Cancer Therapy by Cancer Types
• Total Treated cases by the line of therapies

Download the report to understand which factors are driving Oncolytic Virus Therapies epidemiology trends @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market

Oncolytic Virus Therapies Pipeline Therapies and Key Companies

• ONCOS-102: Targovax
• RP1 (Vusolimogene Oderparepvec): Replimune
• GL-ONC1: Genelux Corporation
• CAN-2409: Candel Therapeutics
• DNX-2401 (Tasadenoturev): DNAtrix
• PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen
• G207: Treovir
• LOAd703: Lokon Pharma AB
• Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
• CG0070: CG Oncology

Learn more about the Oncolytic Virus Therapies in clinical trials @ Oncolytic Virus Therapies Market Dynamics and Trends

Oncolytic Virus Therapies Market Dynamics

Oncolytic viruses have many advantages over other tumor immunotherapies, including high killing efficiency, precise targeting, fewer side effects or drug resistance, and low cost, fueling the oncolytic virus therapies market growth. Furthermore, as certain oncolytic viruses, such as Adeno oncolytic viruses, have demonstrated antitumor memory, they could be used as a cancer vaccine.

In 2015, IMLYGIC (talimogene laherparepvec/T-Vec; Amgen) became the first oncolytic virus approved by the US FDA and later by the European Commission (EC) for the treatment of unresectable melanoma lesions. It harnesses a genetically modified Herpes Simplex Virus Type 1 (HSV-1) to replicate within tumors and stimulate the immune system.

Although these milestones have been achieved, continued progress in oncolytic virotherapy (OV) is evident through clinical trials conducted by major players such as Replimune, DNAtrix, and SillaJen, among others. This signals a promising future for OV therapy in the global fight against various cancers.

Scope of the Oncolytic Cancer Therapies Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Oncolytic Cancer Therapies Companies: Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others
• KeyOncolytic Cancer Therapies in Pipeline: ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, and others
• Therapeutic Assessment: Oncolytic Cancer Therapies current marketed and emerging therapies
• Unmet Needs, KOL’s views, Analyst’s views, Oncolytic Cancer Therapies Market Access and Reimbursement
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Discover more about emerging oncolytic cancer therapies in development @ Oncolytic Virus Cancer Clinical Trials and FDA Approvals

Table of Contents

 1. Oncolytic Virus Therapies Market Key Insights

2. Oncolytic Virus Therapies Market Report Introduction

3. Oncolytic Virus Therapies Market Overview at a Glance

4. Oncolytic Virus Therapies Market Executive Summary

5. Disease Background and Overview

6. Oncolytic Virus Therapies Treatment and Management

7. Oncolytic Virus Therapies Epidemiology and Patient Population

8. Patient Journey

9. Oncolytic Virus Therapies Emerging Drugs

10. 7MM Oncolytic Virus Therapies Market Analysis

11. Oncolytic Virus Therapies Market Outlook

12. Potential of Current and Emerging Therapies

13. KOL Views

14. Oncolytic Virus Therapies Market Drivers

15. Oncolytic Virus Therapies Market Barriers

16. Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oncolytic Virus Therapies Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight